lorlatinib
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
In a phase I/II trial, lorlatinib was safe and effective in ROS1-positive non-small cell lung cancer.
In an observational study, the incidence of infectious events was monitored in 133 patients with acute lymphoblastic leukaemia…
Tyrosine kinase inhibitors (TKI) have achieved great success for cancer patients with aberrant target genes such as ROS1, NTRKs…
The investigational ALK inhibitor lorlatinib, whose early clinical activity was first reported last year, continues to look…
Lorlatinib achieved systemic and intracranial responses in patients with ALK- and ROS1-positive NSCLC.
Data from a phase I study indicate that the investigational ALK inhibitor lorlatinib is active in patients with ALK- or ROS1…
biggest challenges in achieving cure or long-term remission from cancer. In patients who respond and then relapse, treatment with…